What records are connected here?
- Evidence lanes
- 2
- Source years
- 15
- Drugs@FDA applications
- 0
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Not FDA-approved1,2,4Evidence: Smaller human trialsInflammation and immune · Cancer · Infections
Also called Thymalfasin1
Thymosin alpha-1 (Ta1, also called thymalfasin) is a 28-amino-acid peptide first isolated from calf thymus in 1977. It is not an FDA-approved drug, although FDA notes that a product containing it is licensed in other countries.1 In 2024 FDA staff reviewed its use in 12 conditions, including hepatitis B and C, HIV, sepsis and several cancers, and found a lack of evidence of effectiveness for any of them.1 FDA’s advisory committee voted 17 to 4 against adding it to the list of substances pharmacies may use in compounding. Thymosin alpha-1 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.2,6
| What it is | A 28-amino-acid peptide with an acetylated N-terminus, originally isolated from a thymus extract; FDA describes thymalfasin as a chemically synthesized version.1 |
|---|---|
| FDA status | Not FDA-approved. FDA’s 2024 evaluation states that it is not a component of an FDA-approved drug, and FDA lists it among compounding substances that may present significant safety risks.1,4 |
| Human evidence | Many clinical studies, mostly small, including randomized trials in sepsis and melanoma, which FDA found inconclusive and limited by design problems.1 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
Thymosin alpha-1 is a 28-amino-acid peptide, acetylated at one end, that was first isolated in 1977 from thymosin fraction 5, a crude extract of calf thymus, according to FDA’s evaluation.1
FDA states that thymalfasin is a chemically synthesized version of Ta1, and that Zadaxin is a finished product containing it that is available in other countries but is not interchangeable with the bulk substance.1
FDA’s evaluation describes immune-modulating effects attributed to activation of Toll-like receptors on dendritic cells and immune precursor cells, which are thought to explain effects against tumors, sepsis and viruses in laboratory and animal models.1
FDA notes that most of these studies used amounts far higher than those used in people, so their clinical relevance is unclear.1
In a randomized trial of 361 people with severe sepsis, 28-day death rates were 26% with Ta1 and 35% in the control group, which did not reach statistical significance; FDA notes that the trial was not double-blinded.1
Across the 12 uses it reviewed, FDA concluded that studies were inconclusive and limited by small size and design problems, such as missing control groups, lack of blinding and outdated comparison treatments.1
FDA reports that in most studies Ta1 was well tolerated, with irritation where it was given being the most common reaction, but that safety data are insufficient for some proposed uses, such as after stem cell transplants or alongside flu vaccines.1
Evidence-strength label: Smaller controlled human trials. How this label is assigned
No. FDA’s evaluation, dated November 15, 2024, states that neither Ta1 nor its acetate salt is a component of an FDA-approved drug, and that there is no United States Pharmacopeia monograph for either.1
FDA staff evaluated both forms for the 503A bulks list, the list of substances pharmacies may use in compounding, and concluded that the balance of criteria weighs against adding them.1
A Federal Register notice announced the December 4, 2024 advisory-committee meeting that discussed thymosin alpha-1. According to the minutes, the committee voted 17 to 4 against placing each form on the list.2,3
FDA’s compounding safety-risk page, current as of April 22, 2026, lists thymosin alpha-1 among substances whose nominations were withdrawn, citing a possible significant risk of immune reactions and inadequate safety information.4
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Thymosin alpha-1 is not among them.5,6
Whether it helps in any of the conditions FDA reviewed when added to current standard care, which FDA states is unknown because many studies used outdated treatments.1
FDA’s final decision on the 503A list, which was not part of the sources reviewed through November 15, 2026.1,4
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Thymosin alpha-1: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Thymosin alpha-1 are a bounded selection, not every registration or paper about Thymosin alpha-1. For the years before Thymosin alpha-1 was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Thymosin alpha-1 as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Thymosin alpha-1 in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
Not FDA-approved; FDA advised against adding it to the compounding list. FDA staff recommended in 2024 against adding thymosin alpha-1 to the 503A compounding list, and FDA lists it among substances that may present significant safety risks. It is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
Not FDA-approved; FDA advised against adding it to the compounding list. FDA staff recommended in 2024 against adding thymosin alpha-1 to the 503A compounding list, and FDA lists it among substances that may present significant safety risks. It is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Clinical trials · source date November 6, 2026
ClinicalTrials.gov record NCT07922954↗Added to PeptideScanner November 15, 2026Clinical trials · added November 15, 2026
ClinicalTrials.gov record NCT07922954↗Source date November 6, 2026Clinical trials · added November 15, 2026
ClinicalTrials.gov record NCT07884201↗Source date October 20, 2026Literature metadata · added November 15, 2026
Clinical Applications and Evidence Landscape of Thymosin Alpha 1 as an Immunomodulatory Adjunct in Cancer Care: A Scoping Review.↗Source date September 29, 2026PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
17 of 18 selected trial records include at least one phase value; 18 of 18 include a status value in the retained structured contract.
A phase value is unavailable here for 1 selected record; this is not counted as “no phase.”
30 of 30 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT00001036 at 2026-11-15T22:10:40.222Z. Its registry update date was 2008-07-30, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.
PeptideScanner retained ClinicalTrials.gov record NCT00711620 at 2026-11-15T22:10:40.222Z. Its registry update date was 2011-06-14, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.
PeptideScanner retained ClinicalTrials.gov record NCT00911443 at 2026-11-15T22:10:40.222Z. Its registry update date was 2009-07-09, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.
30 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Selected records span July 30, 2008 to November 6, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07922954 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-11-06, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07884201 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-10-20, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.↗
Literature metadata
PubMed lists PMID 42797537 in Pharmaceuticals (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2026-09-19 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 41749205 in BMC medicine as Journal Article, Clinical Trial, Phase II, with publication-date metadata of 2026-02-26 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07780721 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06139419 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06024356 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-06-18, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04428008 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06461910 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-03-03, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.↗
Literature metadata
PubMed lists PMID 15546255 in Journal of gastroenterology and hepatology as Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 20536460 in Annals of the New York Academy of Sciences as Journal Article, Review, with publication-date metadata of 2010-04 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 20536462 in Annals of the New York Academy of Sciences as Journal Article, Review, with publication-date metadata of 2010-04 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
Federal Register via GovInfo · Official source · Source checked August 21, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026